keyword
MENU ▼
Read by QxMD icon Read
search

Blood and Marrow transplant

keyword
https://www.readbyqxmd.com/read/28092354/use-of-defibrotide-to-treat-transplant-associated-thrombotic-microangiopathy-a-retrospective-study-of-the-paediatric-diseases-and-inborn-errors-working-parties-of-the-european-society-of-blood-and-marrow-transplantation
#1
L Yeates, M A Slatter, S Bonanomi, F L W I Lim, S Y Ong, A Dalissier, W Barberi, A Shulz, M Duval, C Heilmann, A Willekens, W H Y Hwang, C Uderzo, P Bader, A R Gennery
No abstract text is available yet for this article.
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28092353/non-myeloablative-conditioning-for-second-hematopoietic-cell-transplantation-for-graft-failure-in-patients-with-non-malignant-disorders-a-prospective-study-and-review-of-the-literature
#2
K Mallhi, P J Orchard, W P Miller, Q Cao, J Tolar, T C Lund
Allogeneic hematopoietic cell transplantation (HCT) effectively treats several non-malignant disorders such as selected lysosomal disorders, cerebral adrenoleukodystrophy and hemoglobinopathies. However, rates of graft failure (GF) in non-malignant populations exceed those of patients with malignant indications for HCT. Salvage conditioning regimens and outcomes for second HCT for GF vary immensely in the literature. We report 17 consecutive pediatric patients with non-malignant disorders who underwent a second allogenic HCT for GF using a non-myeloablative, low-dose busulfan-based regimen...
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28091736/salvage-therapy-for-acute-chemorefractory-leukemia-by-allogeneic-stem-cell-transplantation-the-korean-experience
#3
Shin Hye Yoo, Youngil Koh, Dae-Young Kim, Jung-Hee Lee, Je-Hwan Lee, Kyoo-Hyung Lee, Sung-Soo Yoon, Seonyang Park, Sung-Kyu Park, Dae-Sik Hong, Hyeon Gyu Yi, Chul-Soo Kim, Ji Eun Jang, June-Won Cheong, Joonho Moon, Yoo Hong Min, Sang Kyun Sohn, Inho Kim
Little is known about the characteristics that make patients with acute leukemia suitable for undergoing salvage therapy by allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we analyzed the clinical outcomes of 223 patients with acute leukemia who underwent allo-HSCT while not in complete remission (CR). The primary end points were overall survival (OS) and CR rate. CR was achieved in 79.8% of patients after allo-HSCT. Acute graft-versus-host disease (GVHD) was significantly associated with CR (P = 0...
January 16, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28091601/massively-parallel-digital-transcriptional-profiling-of-single-cells
#4
Grace X Y Zheng, Jessica M Terry, Phillip Belgrader, Paul Ryvkin, Zachary W Bent, Ryan Wilson, Solongo B Ziraldo, Tobias D Wheeler, Geoff P McDermott, Junjie Zhu, Mark T Gregory, Joe Shuga, Luz Montesclaros, Jason G Underwood, Donald A Masquelier, Stefanie Y Nishimura, Michael Schnall-Levin, Paul W Wyatt, Christopher M Hindson, Rajiv Bharadwaj, Alexander Wong, Kevin D Ness, Lan W Beppu, H Joachim Deeg, Christopher McFarland, Keith R Loeb, William J Valente, Nolan G Ericson, Emily A Stevens, Jerald P Radich, Tarjei S Mikkelsen, Benjamin J Hindson, Jason H Bielas
Characterizing the transcriptome of individual cells is fundamental to understanding complex biological systems. We describe a droplet-based system that enables 3' mRNA counting of tens of thousands of single cells per sample. Cell encapsulation, of up to 8 samples at a time, takes place in ∼6 min, with ∼50% cell capture efficiency. To demonstrate the system's technical performance, we collected transcriptome data from ∼250k single cells across 29 samples. We validated the sensitivity of the system and its ability to detect rare populations using cell lines and synthetic RNAs...
January 16, 2017: Nature Communications
https://www.readbyqxmd.com/read/28090375/autologous-bone-marrow-transplantation-in-multiple-sclerosis-biomarker-relevance-for-patient-recruitment-and-follow-up
#5
Ana C Londoño, Carlos A Mora
BACKGROUND: Despite the current availability of disease modifying therapies for the treatment of multiple sclerosis, there are still patients who suffer from severe neurological dysfunction in the relapsing-remitting or early progressive forms of the disease. For these patients autologous hematopoietic stem cell transplant offers an important therapeutic solution to prevent progression to irreversible disability. In spite of multiple studies in the last two decades, patient inclusion criteria, protocols for peripheral blood stem cell mobilization and bone marrow cell conditioning and methodology of follow up for autologous hematopoietic stem cell transplant in multiple sclerosis have not been strictly unified...
October 2016: Journal of Clinical & Cellular Immunology
https://www.readbyqxmd.com/read/28087884/the-role-of-immunoglobulin-prophylaxis-for-prevention-of-cytomegalovirus-infection-in-pediatric-hematopoietic-stem-cell-transplantation-recipients
#6
Gal Goldstein, Tal Frenkel Rutenberg, Sarina Levy Mendelovich, Daphna Hutt, Michal Teperberg Oikawa, Amos Toren, Bella Bielorai
BACKGROUND: Following cessation of intravenous immunoglobulin (IVIg) administration for allogeneic hematopoietic stem cell transplantation (HSCT) recipients at our unit, we observed a sharp decline in the incidence of cytomegalovirus (CMV) infection. PROCEDURE: We conducted a retrospective study of the role of IVIg in the prevention of CMV infection in children and young adults who underwent HSCT from matched related donor. RESULTS: We included 109 patients (IVIg+/IVIg- ratio 82/27)...
January 14, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28068510/current-knowledge-and-priorities-for-future-research-in-late-effects-after-hematopoietic-stem-cell-transplantation-hct-for-severe-combined-immunodeficiency-patients-a-consensus-statement-from-the-second-pediatric-blood-and-marrow-transplant-consortium-international
#7
REVIEW
Jennifer Heimall, Jennifer Puck, Rebecca Buckley, Thomas A Fleisher, Andrew R Gennery, Benedicte Neven, Mary Slatter, Elie Haddad, Luigi D Notarangelo, K Scott Baker, Andrew C Dietz, Christine Duncan, Michael A Pulsipher, Mort J Cowan
Severe combined immunodeficiency (SCID) is 1 of the most common indications for pediatric hematopoietic cell transplantation (HCT) in patients with primary immunodeficiency. Historically, SCID was diagnosed in infants who presented with opportunistic infections within the first year of life. With newborn screening (NBS) for SCID in most of the United States, the majority of infants with SCID are now diagnosed and treated in the first 3.5 months of life; however, in the rest of the world, the lack of NBS means that most infants with SCID still present with infections...
January 6, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28068509/erratum-to-reduced-intensity-conditioning-combined-with-188-rhenium-radioimmunotherapy-before-allogeneic-hematopoietic-stem-cell-transplantation-in-elderly-patients-with-acute-myeloid-leukemia-the-role-of-in-vivo-t-cell-depletion-biol-blood-marrow-transplant
#8
Sebastian Schneider, Annette Strumpf, Johannes Schetelig, Gerd Wunderlich, Gerhard Ehninger, Jörg Kotzerke, Martin Bornhäuser
No abstract text is available yet for this article.
January 6, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28067880/a-phase-i-ii-trial-of-intrabone-marrow-cord-blood-transplantation-and-comparison-of-the-hematological-recovery-with-the-japanese-nationwide-database
#9
N Kurita, M Gosho, Y Yokoyama, T Kato, N Obara, M Sakata-Yanagimoto, Y Hasegawa, N Uchida, S Takahashi, Y Kouzai, Y Atsuta, M Kurata, T Ichinohe, S Chiba
Intrabone marrow cord blood transplantation (IB-CBT) was proposed as a promising treatment modality to improve hematological recovery. However, clinical advantages of IB-CBT over conventional IV CBT have been unclear. We conducted a prospective single-center trial of IB-CBT to evaluate its safety and superiority in terms of hematological recovery. Fifteen adults with hematological malignancies were enrolled. A thawed and unwashed single cord blood unit was injected into the bilateral superior-posterior iliac crests under local anesthesia...
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28067879/impact-of-t-cell-chimerism-on-relapse-after-cord-blood-transplantation-for-hematological-malignancies-nagoya-blood-and-marrow-transplantation-group-study
#10
E Yokohata, Y Kuwatsuka, H Ohashi, S Terakura, N Kawashima, A Seto, S Kurahashi, Y Ozawa, T Goto, N Imahashi, T Nishida, K Miyao, R Sakemura, T Kato, M Sawa, A Kohno, H Sao, H Iida, H Kiyoi, T Naoe, K Miyamura, M Murata
No abstract text is available yet for this article.
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28067876/impact-of-wilms-tumor-1-expression-on-outcome-of-patients-undergoing-allogeneic-stem-cell-transplantation-for-aml
#11
R Duléry, O Nibourel, J Gauthier, V Elsermans, H Behal, V Coiteux, L Magro, A Renneville, A Marceau, T Boyer, B Quesnel, C Preudhomme, A Duhamel, I Yakoub-Agha
The monitoring of the minimal residual disease by Wilms' tumor 1 expression (MRD(WT1)) is a standardized test, which can be used in over 80% of patients with AML. To investigate the prognostic value of MRD(WT1) in patients undergoing allogeneic stem cell transplantation (allo-SCT) for AML, MRD(WT1) was monitored 3 months after transplantation in 139 patients. MRD(WT1) positivity did not lead to any therapeutic intervention. Median follow-up was 39.3 (6.4-99.8) months. Patients with positive MRD(WT1) at 3 months experienced more often post-transplant relapse (27/30, 90%) than those with negative MRD(WT1) (16/109, 14...
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28067875/factors-predicting-outcome-after-allogeneic-transplant-in-refractory-acute-myeloid-leukemia-a-retrospective-analysis-of-gruppo-italiano-trapianto-di-midollo-osseo-gitmo
#12
E Todisco, F Ciceri, C Boschini, F Giglio, A Bacigalupo, F Patriarca, I Donnini, E P Alessandrino, W Arcese, A P Iori, P Marenco, I Cavattoni, P Chiusolo, E Terruzzi, L Castagna, A Santoro, A Bosi, E Oldani, B Bruno, F Bonifazi, A Rambaldi
The clinical outcome of primary refractory (PRF) AML patients is poor and only a minor proportion of patients is rescued by allogenic hematopoietic stem cell transplantation (HSCT). The identification of pre-HSCT variables may help to determine PRF AML patients who can most likely benefit from HSCT. We analyzed PRF AML patients transplanted between 1999 and 2012 from a sibling, unrelated donor or a cord blood unit. Overall, 227 patients from 26 Gruppo Italiano Trapianto di Midollo Osseo e Terapia cellulare centers were included in the analysis...
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28067872/reduced-intensity-and-non-myeloablative-allogeneic-stem-cell-transplantation-from-alternative-hla-mismatched-donors-for-hodgkin-lymphoma-a-study-by-the-french-society-of-bone-marrow-transplantation-and-cellular-therapy
#13
J Gauthier, L Castagna, F Garnier, T Guillaume, G Socié, S Maury, N Maillard, R Tabrizi, T Marchand, J Malfuson, A Gac, E Gyan, M Mercier, Y Béguin, J Delage, P Turlure, A Marçais, S Nguyen, R Dulery, J Bay, A Huynh, E Daguindau, J Cornillon, C Régny, M Michallet, R Peffault de Latour, I Yakoub-Agha, D Blaise
Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or reduced-intensity conditioning (RIC) is considered a valid approach to treat patients with refractory/relapsed Hodgkin lymphoma (HL). When an HLA-matched donor is lacking a graft from a familial haploidentical (HAPLO) donor, a mismatched unrelated donor (MMUD) or cord blood (CB) might be considered. In this retrospective study, we compared the outcome of patients with HL undergoing a RIC or NMA allo-SCT from HAPLO, MMUD or CB...
January 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28065838/current-results-and-future-research-priorities-in-late-effects-after-hematopoietic-stem-cell-transplantation-hct-for-children-with-sickle-cell-disease-and-thalassemia-a-consensus-statement-from-the-second-pediatric-blood-and-marrow-transplant-consortium-international
#14
Shalini Shenoy, Emanuele Angelucci, Staci D Arnold, K Scott Baker, Monica Bhatia, Dorine Bresters, Andrew C Dietz, Josu De La Fuente, Christine Duncan, Javid Gaziev, Allison A King, Michael A Pulsipher, Angela Smith, Mark C Walters
Sustained donor engraftment after allogeneic hematopoietic cell transplantation (HCT) converts to healthy donor hemoglobin synthesis and halts disease symptoms in patients with sickle cell disease (SCD) and thalassemia major. A disease free survival probability that exceeds 90% has been reported when HCT using an HLA-matched sibling donor is performed in young patients with low risk disease or treatment related risk factors. Alternate donor HCT and HCT in adults is performed infrequently due to a higher risk profile...
January 5, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28062215/next-generation-sequencing-in-adult-b-cell-acute-lymphoblastic-leukemia-patients
#15
Olga Sala Torra, Megan Othus, David W Williamson, Brent Wood, Ilan Kirsch, Harlan Robins, Lan Beppu, Margaret R O'Donnell, Stephen J Forman, Frederick R Appelbaum, Jerald P Radich
We used next generation sequencing (NGS) of the immunoglobulin genes to evaluate residual disease in 153 specimens from 32 patients with adult B cell ALL enrolled in a single, multi-center study. The sequencing results were compared to multi-parameter flow cytometry (MFC) data in 66 specimens (25 patients) analyzed by both methods. There was a strong concordance (82%) between the methods in the qualitative determination of the presence of disease. However, in 17% of cases leukemia was detected by sequencing, but not by MFC...
January 3, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28060252/transduction-transplantation-mouse-model-of-myeloproliferative-neoplasm
#16
Thanh Kim Nguyen, Sarah J Morse, Angela G Fleischman
Transduction-transplantation is a quick and efficient way to model human hematologic malignancies in mice. This technique results in expression of the gene of interest in hematopoietic cells and can be used to study the gene's role in normal and/or malignant hematopoiesis. This protocol provides a detailed description on how to perform transduction-transplantation using calreticulin (CALR) mutations recently identified in myeloproliferative neoplasm (MPN) as an example. In this protocol whole bone marrow cells from 5-flurouracil (5-FU) treated donor mice are transduced with a retrovirus encoding mutant CALR and transplanted into lethally irradiated syngeneic hosts...
December 22, 2016: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/28053635/relapse-of-biphenotypic-acute-leukemia-as-a-breast-mass
#17
Hee-Chul Shin
In acute leukemia, leukemic infiltration of the breast is extremely rare. We report a case of biphenotypic acute leukemia (BAL) that presented as a breast mass. A 30-year-old woman presented with a 4-month history of a right breast mass with nipple discharge and easy fatigue. She had received chemotherapy and peripheral blood stem cell transplantation for BAL and had been in complete remission for the last 2 years. Core needle biopsy of the breast mass revealed monomorphous infiltrates of blast cells with round nuclei and fine chromatin, consistent with leukemic infiltration...
December 2016: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28052366/impact-of-fab-classification-on-predicting-outcome-in-acute-myeloid-leukemia-not-otherwise-specified-patients-undergoing-allogeneic-stem-cell-transplantation-in-cr1-an-analysis-of-1690-patients-from-the-acute-leukemia-working-party-of-ebmt
#18
Jonathan Canaani, Eric Beohou, Myriam Labopin, Gerard Socié, Anne Huynh, Liisa Volin, Jan Cornelissen, Noel Milpied, Tobias Gedde-Dahl, Eric Deconinck, Nathalie Fegueux, Didier Blaise, Mohamad Mohty, Arnon Nagler
The French, American, and British (FAB) classification system for acute myeloid leukemia (AML) is extensively used and is incorporated into the AML, not otherwise specified (NOS) category in the 2016 WHO edition of myeloid neoplasm classification. While recent data proposes that FAB classification does not provide additional prognostic information for patients for whom NPM1 status is available, it is unknown whether FAB still retains a current prognostic role in predicting outcome of AML patients undergoing allogeneic stem cell transplantation...
January 4, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28049637/low-immunosuppressive-burden-after-hla-matched-related-or-unrelated-bmt-using-post-transplantation-cyclophosphamide
#19
Christopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, Marianna Zahurak, Nadira Durakovic, Terry Furlong, Marco Mielcarek, Marta Medeot, Ivana Gojo, B Douglas Smith, Jennifer A Kanakry, Ivan M Borrello, Robert A Brodsky, Douglas E Gladstone, Carol Ann Huff, William H Matsui, Lode J Swinnen, Kenneth R Cooke, Richard F Ambinder, Ephraim J Fuchs, Marcos J de Lima, Borje S Andersson, Ravi Varadhan, Paul V O'Donnell, Richard J Jones, Leo Luznik
The intensive and prolonged immunosuppressive therapy required to prevent or treat graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT) puts patients at substantial risk for life-threatening infections, organ toxicity, and disease relapse. Post-transplantation cyclophosphamide (PTCy) can function as single-agent GVHD prophylaxis after myeloablative, HLA-matched-related (MRD) or HLA-matched-unrelated (MUD) T-cell-replete bone marrow allografting, obviating the need for additional prophylactic immunosuppression...
January 3, 2017: Blood
https://www.readbyqxmd.com/read/28045930/the-ccl2-ccr2-axis-affects-transmigration-and-proliferation-but-not-resistance-to-chemotherapy-of-acute-myeloid-leukemia-cells
#20
Patricia Macanas-Pirard, Thomas Quezada, Leonardo Navarrete, Richard Broekhuizen, Andrea Leisewitz, Bruno Nervi, Pablo A Ramírez
Acute myeloid leukemia (AML) has a high mortality rate despite chemotherapy and transplantation. Both CXCR4/SDF-1 and VLA-4/VCAM1 axes are involved in leukemia protection but little is known about the role of CCL2/CCR2 in AML biology and protection against chemotherapy. We measured CCR2 expression in AML cell lines and primary AML cells by flow cytometry (FCM), real time PCR (RT-PCR) and western blot (WB). CCL2 production was quantified by solid phase ELISA in peripheral blood (PB) and bone marrow (BM) serum...
2017: PloS One
keyword
keyword
68470
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"